ARK Genomic Revolution ETF (ARKG)

Cboe US Currently down 0.03 (-0.08%) in today's trading session

1 member of Congress has disclosed 5 trades in ARK Genomic Revolution ETF (ARKG) via STOCK Act filings. The most recent disclosure was a sale by Dwight Evans on 25 March 2022. Aggregate disclosed activity totals roughly $8K in purchases and $32K in sales (midpoint estimates from bracketed disclosure amounts).

ARK Genomic Revolution ETF is currently trading at $38.82, positioned at 74% of its 52-week range ($22.73 – $44.47).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$38.82
24h Change
-0.03 (-0.08%)
52 Week Range
$22.73$44.47
View on NASDAQ

ARK Genomic Revolution ETF Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ARKG

Select to highlight on chart
3 transactions
Compliance: 60%
Dwight Evans25 Mar 202225 Apr 2022SaleStock$1,001 - $15,000N/A
Dwight Evans25 Mar 202225 Apr 2022SaleStock$1,001 - $15,000N/A
Dwight Evans2 Nov 202122 Dec 2021SaleStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$1.18B

Volume

1.46M

Beta

2.38

P/E Ratio

Fundamentals

EPS

Div. Yield

0.99%

Open

$38.44

Day Range

$38.44 — $39.46

Company Information

Sector
Financial Services
Industry
Asset Management
Exchange
CBOE · USD
Country
US
IPO Date
2014-10-31

The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical mark...

No earnings data available for this stock.

Dividends

Dividend History

29 Dec 2021
Amount $0.3824
29 Dec 2020
Amount $0.7901
27 Dec 2019
Amount $1.0539
27 Dec 2018
Amount $0.4663
27 Dec 2017
Amount $0.3277

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about ARKG

Which members of Congress have traded ARKG?
1 member of Congress has disclosed 5 trade in ARK Genomic Revolution ETF (ARKG) under the STOCK Act: Dwight Evans.
When was ARKG most recently disclosed by Congress?
The most recent ARKG disclosure was a sale by Dwight Evans on 25 March 2022.
What is the total disclosed congressional trading volume for ARKG?
Members of Congress have disclosed approximately $8K in ARKG purchases and $32K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in ARKG?
This ARKG page updates as soon as new STOCK Act disclosures are filed for ARK Genomic Revolution ETF. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.